James A. Boiani
FDA’s LDT Proposed Rule Heads to the White House
Administrative and Regulatory ·
Unpacking Averages: Analyzing the Relationship Between MDRs and Recalls
Health Care and Life Sciences ·
TAKE TWO: CMS’s Second Attempt to Streamline Breakthrough Device Coverage Limited to 5 Devices Per Year
Health Care and Life Sciences ·
FDA Issues Orphan Drug Exclusivity Policy That Could Be a Catalyst for Future Litigation
Health Care and Life Sciences ·
The VALID Act: Senate Action Brings FDA Regulation of LDTs Closer to Fruition
Health Care and Life Sciences ·